New Zolgensma data suggest comparable efficacy to Spinraza — analysts

As Novartis awaits the FDA decision on its spinal muscular atrophy (SMA) gene-therapy, Zolgensma, the company that developed the treatment for the rare, deadly inherited disorder, AveXis, presented data snapshots from ongoing trials on Sunday, prompting analysts to suggest that the one-shot therapy was looking comparable to Biogen’s approved Spinraza.